Colorectal Cancer Therapy
Adventrx receives U.S. Food and Drug Administration clearance to initiate CoFactor phase III trial
Published in Medical Letter on the CDC and FDA, June 21st, 2006
The company also announced it remains on track to initiate the phase III clinical trial in Q2 2006. CoFactor is a biomodulator drug designed to improve the efficacy and safety of the widely used chemotherapeutic agent, 5-fluorouracil (5-FU).
The SPA documents the FDA's agreement that the design and planned analysis of the phase III study adequately address the objectives necessary to support a regulatory submission for...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Carcinogenesis
Bromate mutagenicity is due to oxidative damage causing chromosomal breakage - Child Abuse
Effects of abuse and related adverse experiences in childhood are long lasting - Genetics & Genomics
Gene expression correlates of unexplained fatigue are reported - HIV/AIDS Therapy
Strong HIV prevention programs provide lessons for effective interventions - Polio Vaccine
Reversions in 5'-untranslated region of poliovirus after vaccination are analyzed - Abdominal Aortic Aneurysms
Endologix receives U.S. Food and Drug Administration approval for Visiflex Delivery System - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
